Skip to main content
editorial
. 2017 May 10;8(5):820–822. doi: 10.1039/c7md90012k

Fig. 1. X-ray crystal structure of gefitinib in wild-type EGFR showing close proximity of the compound with the threonine gatekeeper (left). Modelled structure of osimertinib in T790M mutant of EGFR showing close proximity with the methionine gatekeeper residue and also covalent bond to Cys-797 (right).

Fig. 1